Jump to main content
Jump to site search
Access to RSC content Close the message box

Continue to access RSC content when you are not at your institution. Follow our step-by-step guide.


Issue 3, 2014
Previous Article Next Article

Luminescent iminophosphorane gold, palladium and platinum complexes as potential anticancer agents

Author affiliations

Abstract

A series of coordination gold(III), palladium(II), and platinum(II) complexes with a luminescent iminophosphorane ligand derived from 8-aminoquinoline [Ph3P[double bond, length as m-dash]N–C9H6N] (1) have been synthesized and structurally characterized. The coordination palladium(II) and platinum(II) compounds can evolve further, under appropriate conditions, to give stable cyclometalated endo species [M{κ3-C,N,N-C6H4(PPh2[double bond, length as m-dash]N-8-C9H6N)}Cl] (M = Pd, Pt) by C–H activation of the phenyl group of the PPh3 fragment. Iminophosphorane 1 and the new metallic complexes are luminescent in DMSO or DMSO–H2O (1 : 1 mixture) solutions at RT. The compounds have been evaluated for their antiproliferative properties in a human ovarian cancer cell line (A2780S), in human lung cancer cells (A549) and in a non-tumorigenic human embryonic kidney cell line (HEK-293T). Most compounds have been more toxic to the ovarian cancer cell line than to the non-tumorigenic cell line. The new complexes interact with human serum albumin (HSA) faster than cisplatin. Studies of the interactions of the compounds with DNA indicate that, in some cases, they exert anticancer effects in vitro based on different mechanisms of action with respect to cisplatin.

Graphical abstract: Luminescent iminophosphorane gold, palladium and platinum complexes as potential anticancer agents

Back to tab navigation

Supplementary files

Article information


Submitted
11 Jan 2014
Accepted
20 Feb 2014
First published
07 Mar 2014

Inorg. Chem. Front., 2014,1, 231-241
Article type
Paper
Author version available

Luminescent iminophosphorane gold, palladium and platinum complexes as potential anticancer agents

M. Frik, J. Jiménez, V. Vasilevski, M. Carreira, A. de Almeida, E. Gascón, F. Benoit, M. Sanaú, A. Casini and M. Contel, Inorg. Chem. Front., 2014, 1, 231
DOI: 10.1039/C4QI00003J

Social activity

Search articles by author

Spotlight

Advertisements